Importance of the Test
- Determines the viability of using immunotherapy drugs.
- Avoids treatments that cancer cells may not respond to.
- Provides accurate information on tumor behavior and immune interaction.
Book PD-L1 IHC Testing in Saudi Arabia | Lahalak Medical Platform
This advanced diagnostic test determines tumor responsiveness to immunotherapy, ensuring the selection of the most effective personalized treatment plan to optimize recovery outcomes and minimize unnecessary side effects for cancer patients.
Scientific name: PD-L1 Immunohistochemistry (IHC) Testing
A specialized laboratory test measuring PD-L1 protein expression on tumor cells. It guides oncologists in selecting appropriate immunotherapy drugs, particularly for lung, bladder, and melanoma cancers.
Service type
Histopathology Laboratory Test
Duration
20-30 minutes (Sample Submission)
Fasting
Fasting is not required
Included Services
- Tissue sample analysis
- Detailed protein expression report
- Result review by a Consultant Pathologist
Medical Service Information
When is this test needed?
- Non-Small Cell Lung Cancer (NSCLC).
- Bladder and urothelial cancers.
- Melanoma (Skin Cancer).
- Triple-Negative Breast Cancer.
Understanding Results
- Positive Result: High protein expression suggests benefit from immunotherapy.
- Negative Result: May indicate the need for alternative treatments like chemotherapy.
- Decisions are often based on the Tumor Proportion Score (TPS).
Conditions & Notices
- A properly preserved tissue sample (biopsy) must be provided
- Attach the initial medical report of the case
Medical services you might also like
